1352440-70-0

Basic information

• Product Name: N-(3-ethynylphenyl)-2-hydroxy-5-nitrobenzamide
• Synonyms: N-(3-ethynylphenyl)-2-hydroxy-5-nitrobenzamide
• CAS NO: 1352440-70-0
• Molecular Weight: 282.255
• Mol File: 1352440-70-0.mol

Chemical Properties

• CAS DataBase Reference: N-(3-ethynylphenyl)-2-hydroxy-5-nitrobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-ethynylphenyl)-2-hydroxy-5-nitrobenzamide(1352440-70-0)
• EPA Substance Registry System: N-(3-ethynylphenyl)-2-hydroxy-5-nitrobenzamide(1352440-70-0)

Safety Data

• Hazardous Substances Data: 1352440-70-0(Hazardous Substances Data)

Upstream product

• 96-97-9 5-nitrosalicylic acid 
• 54060-30-9 3-acetylenephenylamine 

Downstream Products

• 1330841-08-1 N-(3-ethynylphenyl)-2-methoxy-5-nitrobenzamide 
• 1304351-75-4 C₁₆H₁₄N₂O₂ 
• 1352440-71-1 C₁₅H₁₂N₂O₂ 
• 1391013-34-5 N-(3-ethynylphenyl)-5-(7-hydroxyamino-7-oxoheptanamido)-2-methoxybenzamide 
• 1352440-60-8 N-(3-ethynylphenyl)-2-hydroxy-5-(8-hydroxyamino-8-oxooctanamido)benzamide 
• 1352440-54-0 N-(3-ethynylphenyl)-2-hydroxy-5-(7-hydroxyamino-7-oxoheptanamido)benzamide 
• 1391013-36-7 7-[3-(N-3-ethynylphenylcarbamoyl)-4-methoxyphenylamino]-7-oxoheptanoic acid 
• 1352440-87-9 ethyl 8-(4-hydroxy-3-(N-3-ethynylphenylcarbamoyl)phenylamino)-8-oxooctanoate 
• 1352440-72-2 ethyl 7-[4-hydroxy-3-(N-3-ethynylphenylcarbamoyl)phenylamino]-7-oxoheptanoate 

Relevant articles and documents

Nusbiarylins, a new class of antimicrobial agents: Rational design of bacterial transcription inhibitors targeting the interaction between the NusB and NusE proteins

Discovery of antibiotics of a novel mode of action is highly required in the fierce battlefield with multi-drug resistant bacterial infections. Previously we have validated the protein-protein interaction between bacterial NusB and NusE proteins as an unp

Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors

A novel series of N-aryl salicylamides with a hydroxamic acid moiety at 5-position were synthesized efficiently. Their activities against EGFR kinase and HDACs were evaluated. All compounds displayed inhibitory activity against EGFR and HDACs. The antiproliferative activities of synthesized compounds were evaluated by MTT method against human cancer cell lines A431, A549 and HL-60. Compound 1o showed the most potent inhibitory activity against A431 and A549. Compounds 1k and 1n exhibited higher potency against HL-60 than gefitinib and SAHA. N-Aryl salicylamides with a hydroxamic acid moiety at 5-position is another new HDAC-EGFR dual inhibitors.